Intelligence · Patents
Patents expiring in 2043
Annual patent cliff calendar for 2043 — US pharmaceutical patents by expiration date.
- Patents
- 1,718
Quick answer
1,718 indexed pharmaceutical patents have expiration dates in 2043. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 11840497
4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
granted -
US 11839594
Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride
granted -
US 11840704
Adeno-associated virus variant capsids and methods of use thereof
granted -
US 11839599
Methods of providing solriamfetol therapy to subjects with impaired renal function
granted -
US 11844843
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
granted -
US 11844816
Compositions and methods for augmenting the nasal microbiome
granted -
US 11844801
Oral compositions of MK2 pathway inhibitor for treatment of immune conditions
granted -
US 11844799
Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic
granted -
US 11844771
Methods of treating acute respiratory distress syndrome using colchicine
granted -
US 11844830
Vaccines for human papilloma virus and methods for using the same
granted -
US 11844769
Use of cysteamine and derivatives thereof to suppress tumor metastases
granted -
US 11844765
Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion protein
granted -
US 11844841
Dosing regimens and related compositions and methods
granted -
US 11845722
Deuterated compounds and uses thereof
granted -
US 11844756
Compositions and methods for treating anemia
granted -
US 11844837
Compositions of a polyorthoester and an organic acid excipient
granted -
US 11845990
Prediction of sleep parameter and response to sleep-inducing compound based on PER3 VNTR genotype
granted -
US 11845931
CRISPR/Cas screening platform to identify genetic modifiers of tau seeding or aggregation
granted -
US 11844874
Lyophilized polymer scaffold compositions, processes for preparation and use in anabolic wound repair
granted -
US 11844764
Agitation process for preparing a carbetocin drug product
granted -
US 11845989
Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors
granted -
US 11845800
Methods for treating or preventing asthma by administering an IL-4R antagonist
granted -
US 11845726
C4-carbonothioate-substituted tryptamine derivatives and methods of using
granted -
US 11844779
PKC-Delta-I inhibitor formulations and uses thereof
granted -
US 11844773
Solid solution compositions and use in chronic inflammation
granted -
US 11845808
Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
granted -
US 11845965
Regulation of gene expression using engineered nucleases
granted -
US 11845963
HSD17B13 variants and uses thereof
granted -
US 11845959
Identification of factor that promotes human HSC self-renewal
granted -
US 11845957
Models of tauopathy
granted -
US 11845937
RNAi agents for inhibiting expression of DUX4, compositions thereof, and methods of use
granted -
US 11845778
Prefusion PIV F immunogens and their use
granted -
US 11845787
DNA antibody constructs for use against HIV
granted -
US 11845752
Substituted imidazo[1,5-a]pyrazines for the treatment of hepatitis B
granted -
US 11845747
Ester and carbonate pyrimidine compounds as JAK kinase inhibitors
granted -
US 11845727
Aldehyde and ketone derivatives of psilocybin and methods of using
granted -
US 11844857
Treating gynecological malignancies with deployable implants
granted -
US 11844867
Method of delivering insulin into a lumen of the intestinal tract using a swallowable drug delivery device
granted -
US 11844805
Formulations of testosterone and methods of treatment therewith
granted -
CA 3259417
DOMAINES VARIABLES UNIQUES D'IMMUNOGLOBULINE CIBLANT LE RÉCEPTEUR DES LYMPHOCYTES T
granted -
US 11851498
Anti-CD276 antibodies (B7H3)
granted -
US 11851471
T-cell modulatory multimeric polypeptides and methods of use thereof
granted -
US 11851655
Compositions and methods for modulating apolipoprotein (a) expression
granted -
US 11851479
Methods and compositions for pertussis diagnosis
granted -
US 11851440
Modulators of eukaryotic initiation factor 2B, compositions and methods
granted -
US 11850236
Method for inhibiting Zika virus infection
granted -
US 11851653
Materials and methods for treatment of alpha-1 antitrypsin deficiency
granted -
US 11850535
Methods for quantitating individual antibodies from a mixture
granted
Frequently asked questions
How many pharma patents expire in 2043?
1,718 published patents in our USPTO index have expiration dates falling in calendar year 2043.